Although Aβ deposition has not been identified as a main contributor to clinical symptomatology in AD, Aβ oligomerization exerts a series of downstream effects that trigger additional pathological effects (e.g. the exacerbation of tau pathology). The gene discussed is MAPT; the disease is Alzheimer disease.